Codelivery of chemotherapeutics via crosslinked multilamellar liposomal vesicles to overcome multidrug resistance in tumor.

Multidrug resistance (MDR) is a significant challenge to effective cancer chemotherapy treatment. However, the development of a drug delivery system that allows for the sustained release of combined drugs with improved vesicle stability could overcome MDR in cancer cells. To achieve this, we have de...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yarong Liu, Jinxu Fang, Kye-Il Joo, Michael K Wong, Pin Wang
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2014
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/924820bd33fd4532844d39131d1bb33b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:924820bd33fd4532844d39131d1bb33b
record_format	dspace
spelling	oai:doaj.org-article:924820bd33fd4532844d39131d1bb33b2021-11-25T05:56:04ZCodelivery of chemotherapeutics via crosslinked multilamellar liposomal vesicles to overcome multidrug resistance in tumor.1932-620310.1371/journal.pone.0110611https://doaj.org/article/924820bd33fd4532844d39131d1bb33b2014-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0110611https://doaj.org/toc/1932-6203Multidrug resistance (MDR) is a significant challenge to effective cancer chemotherapy treatment. However, the development of a drug delivery system that allows for the sustained release of combined drugs with improved vesicle stability could overcome MDR in cancer cells. To achieve this, we have demonstrated codelivery of doxorubicin (Dox) and paclitaxel (PTX) via a crosslinked multilamellar vesicle (cMLV). This combinatorial delivery system achieves enhanced drug accumulation and retention, in turn resulting in improved cytotoxicity against tumor cells, including drug-resistant cells. Moreover, this delivery approach significantly overcomes MDR by reducing the expression of P-glycoprotein (P-gp) in cancer cells, thus improving antitumor activity in vivo. Thus, by enhancing drug delivery to tumors and lowering the apoptotic threshold of individual drugs, this combinatorial delivery system represents a potentially promising multimodal therapeutic strategy to overcome MDR in cancer therapy.Yarong LiuJinxu FangKye-Il JooMichael K WongPin WangPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 10, p e110611 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yarong Liu Jinxu Fang Kye-Il Joo Michael K Wong Pin Wang Codelivery of chemotherapeutics via crosslinked multilamellar liposomal vesicles to overcome multidrug resistance in tumor.
description	Multidrug resistance (MDR) is a significant challenge to effective cancer chemotherapy treatment. However, the development of a drug delivery system that allows for the sustained release of combined drugs with improved vesicle stability could overcome MDR in cancer cells. To achieve this, we have demonstrated codelivery of doxorubicin (Dox) and paclitaxel (PTX) via a crosslinked multilamellar vesicle (cMLV). This combinatorial delivery system achieves enhanced drug accumulation and retention, in turn resulting in improved cytotoxicity against tumor cells, including drug-resistant cells. Moreover, this delivery approach significantly overcomes MDR by reducing the expression of P-glycoprotein (P-gp) in cancer cells, thus improving antitumor activity in vivo. Thus, by enhancing drug delivery to tumors and lowering the apoptotic threshold of individual drugs, this combinatorial delivery system represents a potentially promising multimodal therapeutic strategy to overcome MDR in cancer therapy.
format	article
author	Yarong Liu Jinxu Fang Kye-Il Joo Michael K Wong Pin Wang
author_facet	Yarong Liu Jinxu Fang Kye-Il Joo Michael K Wong Pin Wang
author_sort	Yarong Liu
title	Codelivery of chemotherapeutics via crosslinked multilamellar liposomal vesicles to overcome multidrug resistance in tumor.
title_short	Codelivery of chemotherapeutics via crosslinked multilamellar liposomal vesicles to overcome multidrug resistance in tumor.
title_full	Codelivery of chemotherapeutics via crosslinked multilamellar liposomal vesicles to overcome multidrug resistance in tumor.
title_fullStr	Codelivery of chemotherapeutics via crosslinked multilamellar liposomal vesicles to overcome multidrug resistance in tumor.
title_full_unstemmed	Codelivery of chemotherapeutics via crosslinked multilamellar liposomal vesicles to overcome multidrug resistance in tumor.
title_sort	codelivery of chemotherapeutics via crosslinked multilamellar liposomal vesicles to overcome multidrug resistance in tumor.
publisher	Public Library of Science (PLoS)
publishDate	2014
url	https://doaj.org/article/924820bd33fd4532844d39131d1bb33b
work_keys_str_mv	AT yarongliu codeliveryofchemotherapeuticsviacrosslinkedmultilamellarliposomalvesiclestoovercomemultidrugresistanceintumor AT jinxufang codeliveryofchemotherapeuticsviacrosslinkedmultilamellarliposomalvesiclestoovercomemultidrugresistanceintumor AT kyeiljoo codeliveryofchemotherapeuticsviacrosslinkedmultilamellarliposomalvesiclestoovercomemultidrugresistanceintumor AT michaelkwong codeliveryofchemotherapeuticsviacrosslinkedmultilamellarliposomalvesiclestoovercomemultidrugresistanceintumor AT pinwang codeliveryofchemotherapeuticsviacrosslinkedmultilamellarliposomalvesiclestoovercomemultidrugresistanceintumor
_version_	1718414355008061440

Codelivery of chemotherapeutics via crosslinked multilamellar liposomal vesicles to overcome multidrug resistance in tumor.

Ejemplares similares